| Drug name | Tanezumab |
| Phase | III |
| Indication | Musculoskeletal pain and osteoarthritis |
| Pharmacology description | Nerve growth factor antagonist/monoclonal antibody |
| Route of administration | Injectable |
| Pivotal trial(s) | [35,43] |
Pharmaprojects - copyright to Citeline Drug Intelligence (an Informa business). Readers are referred to Informa-Pipeline (http://informa-pipeline.citeline.com) and Citeline (http://informa.citeline.com).